Search research articles
Contact Us
Filters
Showing results (1111-1120 of 1,142) with videos related to
Page
of 115
Sort By:
JAMA Psychiatry
|
November 24, 2017
Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial
Daniel C Javitt, Cameron S Carter, John H Krystal, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
April 28, 2006
Baseline neurocognitive deficits in the CATIE schizophrenia trial
Richard S E Keefe, Robert M Bilder, Philip D Harvey, et al.
Gut
|
July 17, 2008
Asia Pacific consensus recommendations for colorectal cancer screening
J J Y Sung, J Y W Lau, G P Young, et al.
The International Journal of Neuropsychopharmacology
|
January 10, 2016
Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis
Eric Huang, Clement C Zai, Amanda Lisoway, et al.
The Journal of Allergy and Clinical Immunology
|
February 1, 2020
Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis
Marcus S Shaker, Dana V Wallace, David B K Golden, et al.
Biological Psychiatry Global Open Science
|
July 31, 2023
Illness Phase as a Key Assessment and Intervention Window for Psychosis
Christian G Kohler, Daniel H Wolf, Anissa Abi-Dargham, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
June 3, 2019
New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach
Anna Alkelai, Lior Greenbaum, Erin L Heinzen, et al.
Biological Psychiatry
|
December 15, 2010
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia
Robert W Buchanan, Richard S E Keefe, Jeffrey A Lieberman, et al.
Schizophrenia Research
|
March 3, 2015
A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy
L Fredrik Jarskog, Martin T Lowy, Richard A Grove, et al.
Annals of the New York Academy of Sciences
|
October 29, 2011
Advancing drug discovery for schizophrenia
Stephen R Marder, Bryan Roth, Patrick F Sullivan, et al.
Page
of 115
Search research articles
Search
Showing results (1111-1120 of 1,142) with videos related to
Sort By:
Page
of 115
JAMA Psychiatry
|
November 24, 2017
Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial
Daniel C Javitt, Cameron S Carter, John H Krystal, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
April 28, 2006
Baseline neurocognitive deficits in the CATIE schizophrenia trial
Richard S E Keefe, Robert M Bilder, Philip D Harvey, et al.
Gut
|
July 17, 2008
Asia Pacific consensus recommendations for colorectal cancer screening
J J Y Sung, J Y W Lau, G P Young, et al.
The International Journal of Neuropsychopharmacology
|
January 10, 2016
Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis
Eric Huang, Clement C Zai, Amanda Lisoway, et al.
The Journal of Allergy and Clinical Immunology
|
February 1, 2020
Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis
Marcus S Shaker, Dana V Wallace, David B K Golden, et al.
Biological Psychiatry Global Open Science
|
July 31, 2023
Illness Phase as a Key Assessment and Intervention Window for Psychosis
Christian G Kohler, Daniel H Wolf, Anissa Abi-Dargham, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
June 3, 2019
New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach
Anna Alkelai, Lior Greenbaum, Erin L Heinzen, et al.
Biological Psychiatry
|
December 15, 2010
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia
Robert W Buchanan, Richard S E Keefe, Jeffrey A Lieberman, et al.
Schizophrenia Research
|
March 3, 2015
A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy
L Fredrik Jarskog, Martin T Lowy, Richard A Grove, et al.
Annals of the New York Academy of Sciences
|
October 29, 2011
Advancing drug discovery for schizophrenia
Stephen R Marder, Bryan Roth, Patrick F Sullivan, et al.
Page
of 115